The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
A generic version of lenalidomide capsules has been approved by the FDA for MDS and MM
On October 19, 2021, the U.S. Food and Drug Administration (FDA) approved an abbreviated new drug application for a generic version of lenalidomide capsules, a thalidomide analogue, for oral use in patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS).1 The approval includes 2.5 mg and 20 mg strengths, and a tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths.
Lenalidomide capsules are used for the treatment of adult patients with:
- MM, in combination with multiple regimens for the treatment of newly diagnosed and relapsed/refractory patients.
- MM, as maintenance therapy following autologous hematopoietic stem cell transplantation. Read the National Institute for Health and Care Excellence (NICE) recommendation here.
- Transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. Find out more about this on the MDS Hub.
- Chronic lymphocytic leukemia, only for use as part of controlled clinical trials.
You can find the full prescribing, safety information and black box warning here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content